Actively Recruiting
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
Led by Richmond Research Institute · Updated on 2025-07-23
2000
Participants Needed
1
Research Sites
431 weeks
Total Duration
On this page
Sponsors
R
Richmond Research Institute
Lead Sponsor
R
Richmond Pharmacology Limited
Collaborating Sponsor
AI-Summary
What this Trial Is About
A generic screening study to establish structural and/or functional baselines of specific organs.
CONDITIONS
Official Title
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female volunteers aged 6518 to 6480 years at the date of signing the informed consent.
- Willingness and ability to provide written, personally signed, and dated informed consent.
- Ability and willingness to fully comply with study procedures and restrictions.
- For Part B only: known history of MASLD confirmed by GP diagnosis or documented Fibroscan or liver ultrasound.
You will not qualify if you...
- Known alcoholic liver disease or history of cirrhosis from any cause.
- Any significant previous liver disease such as liver cancer, portal hypertension, or infiltrative liver disease.
- Alcohol consumption greater than 30 units per week.
- Presence of implanted cardiac devices.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge
London, London, United Kingdom, SE1 1YR
Actively Recruiting
Research Team
J
James Rickard
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here